Javier de la Rubia

Caplacizumab Treatment for Acquired Thrombotic Thrombocytopenic Purpura

Marie Scully, Spero R. Cataland, Flora Peyvandi et al. · New England Journal of Medicine · 2019 · 956 citations · Full text

Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial

Sagar Lonial, Brendan M. Weiss, Saad Z. Usmani et al. · The Lancet · 2016 · 842 citations

Hematological Malignancy, Oncology, Daratumumab Monotherapy +6

Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial

Jesús F. San Miguel, Vânia Hungria, Sung‐Soo Yoon et al. · The Lancet Oncology · 2014 · 781 citations

Hematological Malignancy, Double-blind Phase 3, Medicine +9

Lenalidomide and Dexamethasone in Transplant-Ineligible Patients with Myeloma

Lotfi Benboubker, Meletios Α. Dimopoulos, Angela Dispenzieri et al. · New England Journal of Medicine · 2014 · 780 citations · Full text

Lenalidomide plus Dexamethasone for High-Risk Smoldering Multiple Myeloma

María‐Victoria Mateos, Miguel‐Teodoro Hernández, Pilar Giraldo et al. · New England Journal of Medicine · 2013 · 569 citations · Full text